Boston Type 1 Keratoprosthesis: Updated Perspectives
- PMID: 32425503
- PMCID: PMC7196770
- DOI: 10.2147/OPTH.S219270
Boston Type 1 Keratoprosthesis: Updated Perspectives
Abstract
The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implantation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management.
Keywords: Boston keratoprosthesis; corneal transplantation; limbal stem cell deficiency.
© 2020 Nonpassopon et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures



Similar articles
-
The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.Graefes Arch Clin Exp Ophthalmol. 2022 Sep;260(9):2781-2790. doi: 10.1007/s00417-022-05646-1. Epub 2022 Apr 6. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35384455 Review.
-
The Boston keratoprosthesis.Curr Opin Ophthalmol. 2017 Jul;28(4):390-396. doi: 10.1097/ICU.0000000000000373. Curr Opin Ophthalmol. 2017. PMID: 28383302 Review.
-
Boston type I keratoprosthesis: Review.Arq Bras Oftalmol. 2012 May-Jun;75(3):218-22. doi: 10.1590/s0004-27492012000300016. Arq Bras Oftalmol. 2012. PMID: 22872210 Review.
-
Boston type 1 keratoprosthesis outcomes in ocular burns.Acta Ophthalmol. 2013 Sep;91(6):e432-6. doi: 10.1111/aos.12083. Epub 2013 Feb 14. Acta Ophthalmol. 2013. PMID: 23406295
-
The Boston type I keratoprosthesis: improving outcomes and expanding indications.Ophthalmology. 2009 Apr;116(4):640-51. doi: 10.1016/j.ophtha.2008.12.058. Epub 2009 Feb 25. Ophthalmology. 2009. PMID: 19243830
Cited by
-
Outcomes of Boston Keratoprosthesis Type I Implantation in Poland: A Retrospective Study on 118 Patients.J Clin Med. 2024 Feb 8;13(4):975. doi: 10.3390/jcm13040975. J Clin Med. 2024. PMID: 38398288 Free PMC article.
-
Toward electron-beam sterilization of a pre-assembled Boston keratoprosthesis.Ocul Surf. 2021 Apr;20:176-184. doi: 10.1016/j.jtos.2021.02.009. Epub 2021 Mar 3. Ocul Surf. 2021. PMID: 33667673 Free PMC article.
-
Biomechanical Evaluation of Decellularized and Crosslinked Corneal Implants Manufactured From Porcine Corneas as a Treatment Option for Advanced Keratoconus.Front Bioeng Biotechnol. 2022 Apr 14;10:862969. doi: 10.3389/fbioe.2022.862969. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35497356 Free PMC article.
-
Towards Precision Ophthalmology: The Role of 3D Printing and Bioprinting in Oculoplastic Surgery, Retinal, Corneal, and Glaucoma Treatment.Biomimetics (Basel). 2024 Feb 27;9(3):145. doi: 10.3390/biomimetics9030145. Biomimetics (Basel). 2024. PMID: 38534830 Free PMC article. Review.
-
Synergistic Dual Ag/Cu Ion Implantation to Enhance Antimicrobial Defense on Boston Keratoprosthesis.Biomater Res. 2025 Feb 19;29:0147. doi: 10.34133/bmr.0147. eCollection 2025. Biomater Res. 2025. PMID: 39975515 Free PMC article.
References
-
- Chodosh J FDA approval obtained for the Boston Keratoprosthesis type I Lucia design. BOSTON KPro news; July 2019.
Publication types
LinkOut - more resources
Full Text Sources